Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -11.83% is 64% above its 5-year average of -33.04%, near the high end of its 5-year range (-72.90%–-11.83%).
As of the fiscal period ended Tuesday, June 30, 2026. 39.08% above its 12-month average of -19.42%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -11.83%.
RETURN ON EQUITY (ROE)
-11.83%
RETURN ON EQUITY (ROE) AVG TTM
-19.42%
RETURN ON EQUITY (ROE) AVG 3Y
-23.98%
RETURN ON EQUITY (ROE) AVG 5Y
-33.04%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+39.08%
CURRENT VS 3Y AVG
+50.64%
CURRENT VS 5Y AVG
+64.19%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+71.83%
vs the sector median at left
Enliven Therapeutics, Inc.
Market Cap
$3.03B
Return on Equity (ROE)
-11.83%
TTM Avg
-19.42%
3Y Avg
-23.98%
5Y Avg
-33.04%
Market Cap
$3.06B
Return on Equity (ROE)
-61.24%
TTM Avg
-42.47%
3Y Avg
-32.58%
5Y Avg
-25.72%
Market Cap
$2.99B
Return on Equity (ROE)
12.93%
TTM Avg
-48.70%
3Y Avg
-135.42%
5Y Avg
-110.19%
Market Cap
$3.12B
Return on Equity (ROE)
-63.59%
TTM Avg
-115.27%
3Y Avg
-69.35%
5Y Avg
-25.98%
Market Cap
$2.88B
Return on Equity (ROE)
-73.97%
TTM Avg
-48.15%
3Y Avg
-105.34%
5Y Avg
-79.84%
Market Cap
$3.19B
Return on Equity (ROE)
-13.40%
TTM Avg
-35.40%
3Y Avg
-42.99%
5Y Avg
-32.74%
Market Cap
$2.77B
Return on Equity (ROE)
29.28%
TTM Avg
27.86%
3Y Avg
4.54%
5Y Avg
-12.45%
Market Cap
$3.30B
Return on Equity (ROE)
26.08%
TTM Avg
3.42%
3Y Avg
-20.94%
5Y Avg
-16.18%
Market Cap
$3.31B
Return on Equity (ROE)
-130.98%
TTM Avg
-34.38%
3Y Avg
-35.20%
5Y Avg
-30.70%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | $3.03B | -11.83% | -19.42% | -23.98% | -33.04% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.06B | -61.24% | -42.47% | -32.58% | -25.72% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $2.99B | 12.93% | -48.70% | -135.42% | -110.19% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.12B | -63.59% | -115.27% | -69.35% | -25.98% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | -73.97% | -48.15% | -105.34% | -79.84% |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | -13.40% | -35.40% | -42.99% | -32.74% |
| TransMedics Group, Inc. (TMDX)vs › | $2.77B | 29.28% | 27.86% | 4.54% | -12.45% |
| CareDx, Inc (CDNA)vs › | $3.30B | 26.08% | 3.42% | -20.94% | -16.18% |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.31B | -130.98% | -34.38% | -35.20% | -30.70% |
| AtriCure, Inc. (ATRC)vs › | $2.73B | 2.04% | -6.01% | -7.18% | -5.00% |
ROE
-11.8%
ROA
-11.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -11.83% |
| 2026-03-31 | -21.79% |
| 2025-12-31 | -22.56% |
| 2025-09-30 | -20.42% |
| 2025-06-30 | -20.52% |
| 2025-03-31 | -32.89% |
| 2024-12-31 | -28.73% |
| 2024-09-30 | -29.55% |
| 2024-06-30 | -27.16% |
| 2024-03-31 | -25.05% |
| 2023-12-31 | -29.11% |
| 2023-09-30 | -23.60% |
| 2023-06-30 | -18.48% |
| 2023-03-31 | -15.00% |
| 2022-09-30 | -44.71% |
| 2022-06-30 | -64.53% |
| 2022-03-31 | -60.58% |
| 2021-12-31 | -42.54% |
| 2021-09-30 | -48.89% |
| 2021-06-30 | -72.90% |
| 2021-03-31 | -58.74% |
| 2020-12-31 | -48.98% |
| 2020-09-30 | -39.17% |
| 2020-06-30 | -29.44% |
| 2020-03-31 | -25.18% |
| 2019-12-31 | -81.14% |
